Applications of Lipid-based Nanocarriers for Parenteral Drug Delivery

Curr Med Chem. 2022;29(24):4152-4169. doi: 10.2174/0929867329666220104111949.

Abstract

This review describes the use of lipid-based nanocarriers (LNCs) for the parenteral delivery of pharmaceutical actives. Firstly, the two generations of LNCs, namely solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), are explained in terms of preparation, characterization and stability. Although the use of LNCs through parenteral administration has shown many benefits, their use is limited by opsonization, an immune process that causes their short half-life (3-5 min). Therefore, many strategies are discussed to realize "stealth" systems suitable for parenteral administration. The requirements and applications of parenteral lipid nanoparticles are reviewed for the delivery of natural compounds, synthetic drugs and genetic materials. Recently, the latter application has been of remarkable interest due to the numerous benefits of mRNA vaccines to fight the Covid-19 pandemic.

Keywords: Covid-19; Lipid nanoparticles; mRNA vaccine; parenteral drug delivery; phytocompounds; synthetic drugs.

Publication types

  • Review

MeSH terms

  • COVID-19 Drug Treatment*
  • Drug Carriers
  • Drug Delivery Systems
  • Humans
  • Lipids
  • Liposomes
  • Nanoparticles*
  • Pandemics
  • Particle Size

Substances

  • Drug Carriers
  • Lipid Nanoparticles
  • Lipids
  • Liposomes